Abbvie Inc ABBV

$266.69 +0.93 (0.35%)

Valuation

Market cap
469,542,912,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.18
Forward PE
18.71
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
4,501,000
Avg volume
4,696,388
Day's range
$260.62 – $268.86
Shares out
1,766,793,000
Stochastic %K
80%
Beta
0.24
Analysts
Strong Sell
Price target
$278.20

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Oct 7, 5:04 AM
$MRNA $SLS $ABBV SLS Phase 3 Patients Living 3x 4x longer than on SOC/BAT / Just Like in ALL PRIOR GPS Trials.... • Gps Phase 2 MOS 67.6 Months AML CR1 Remission / BAT MOS 24.7 • Gps Phase 2 MOS 21 Months AML CR2 Remission / BAT 8/10 months • Gps Ph1 Mesothelioma 27.8 Months / 27 WEEKS .... and BAT has FAILED 5 AML Trials in the Last Year... • $MRNA added $50B to its mcap based on P3 Cancer Vaccine Data, from $20 to $200… SLS is about to do something similar. its not complicated
0 replies
SuperGreenToday Oct 7, 1:10 AM
$ABBV Share Price: $266.79 Contract Selected: Oct 30, 2026 $265 Calls Buy Zone: $7.14 – $8.82 Target Zone: $12.37 – $15.12 Potential Upside: 64% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
55X_ROI_Q1_2026 Oct 6, 5:23 PM
$MRNA $SLS $ABBV Yes I left the VIALE-C - C Trial Failure off the List.... https://aml-hub.com/medical-information/phase-iii-viale-c-trial-or-venetoclax-ldac-fails-to-show-improvement-in-os-for-newly-diagnosed-patients-with-aml-who-are-ineligible-for-intensive-induction-therapy
0 replies
55X_ROI_Q1_2026 Oct 6, 5:20 PM
$SLS $ABBV $MRNA https://www.onclive.com/view/verona-trial-misses-primary-end-point-of-os-benefit-with-azacitidine-venetoclax-in-higher-risk-mds
1 replies
55X_ROI_Q1_2026 Oct 6, 4:15 PM
$SLS BAT for Control Arm Patients / Aza+VEN / Onureg + Venclexta FAILED to Increase Overall Survival in 5 TRIALS in the last 12 months. • VERONA Phase 3 $ABBV FAILED high risk MDS/AML Precursor • VIALE-M Phase 3 $ABBV FAILED - AML FIRST REMISSION (CR1) • VIALE-T Phase 3 $ABBV FAILED - AML Post Transplant Maintenance • Opti-AML Phase 2 MDACC Reduced Intensity FAILED • Paradigm Phase 2 AML Front Line Modified Dosing again FAILED to Increase Survival.
0 replies
55X_ROI_Q1_2026 Oct 6, 3:50 PM
$MRNA $SLS $ABBV https://stocktwits.com/Szepen/message/665822424
0 replies
55X_ROI_Q1_2026 Oct 6, 3:40 PM
$SLS VIALE-M Phase 3 $ABBV FAILED - AML FIRST REMISSION (CR1) BAT / Onureg + Venclexta / Aza+VEN --- has proven effective in achieving Remission / but not durable Survival - and has failed in trial after trial. • Oral Aza / Onureg is BAT for AML First Remission (CR1) MOS 24.7 Months. • Adding Venetoclax to Onureg, with 8 different dosing attempts - FAILED in the VIALE-M Phase 3 Trial. • Gps Phase 2 MOS in CR1 was not reached and > 67.6 months - BAT 24.7 • Gps Phase 2 MOS in CR2 was stat sig 21 months, in an OLDER, ALL MRD+ set of patients who rec'd much less Gps than P3 GPS Patients. SLS is the Next $MRNA --- now you know.
0 replies
55X_ROI_Q1_2026 Oct 6, 3:29 PM
$MRNA $SLS While we are seeing extended near miraculous ALL Pooled Survival in the SLS REGAL Phase 3 - nearly 40% Survival at 3 years - in a transplant ineligible, Post Salvage AML Second Remission (CR2) Population with a expected MOS of just 6-8 months. BAT / Aza+VEN / Onureg + Venclexta FAILED to Increase OS in 5 TRIALS: • VERONA Phase 3 $ABBV FAILED high risk MDS/AML Precursor • VIALE-M Phase 3 $ABBV FAILED - AML FIRST REMISSION (CR1) • VIALE-T Phase 3 $ABBV FAILED - AML Post Transplant Maintenance • Opti-AML Phase 2 MDACC Reduced Intensity FAILED • Paradigm Phase 2 AML Front Line Modified Dosing again FAILED to Increase Survival.
0 replies